François Martelet M.D Netscientific Chief Executive Officer speaks about Netscientific transatlantic healthcare technology group. NetScientific is a transatlantic healthcare IP commercialisation group. We fund and develop companies that significantly improve the health and well-being of people with chronic diseases. Through our US-UK network, we source, develop and manage early/mid-stage healthcare technology companies focused on Diagnostics, [...]
NetScientific plc (LON:NSCI) chief executive and chairman Francois Martelet hailed recent news from portfolio company Vortex Biosciences as a "very important" milestone. Vortex has been awarded a CE Mark for its circulating tumour cell (CTC) capture system and has registered a Class I medical device with the US FDA (Food and Drug Administration). It means [...]
Biomedical and healthcare incubator NetScientific PLC (LON:NSCI) had a busy first half to the year, focusing on “execution, execution, execution”, according to chief executive officer François Martelet. Backed by its world class scientific advisory boards, the investment company’s emphasis has been on accelerating its core portfolio companies - Wanda, Vortex Biosciences, Glycotest and ProAxsis - [...]
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.